Merus B.V. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line…Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

   Enrollment closed, study ongoing

   Also in this update: Trial sites reduced: 205 → 202 locations

   Merus B.V.·Phase 3· NCT06525220· Registry history of NCT06525220 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

2. Minor

   Petosemtamab Compared With Investigator's Choice Monotherapy in…Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

   Trial sites reduced: 197 → 194 locations

   And 1 more change in the last 30 days

   Merus B.V.·Phase 3· NCT06496178· Registry history of NCT06496178 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.